Connect with us:   Email This Page  | Print
The information on this site is designed for patients. If you are a healthcare professional, click here.
Learn more about Neuronetics, developer of the NeuroStar TMS Therapy System.
NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode.
Find a Provider

Major depression is a serious medical illness affecting more than 14 million American adults every year.1 Often a debilitating disorder, depression results in a persistent state of sadness which interferes with an individual’s thoughts, behavior, mood, and physical health. Learn more about depression symptoms.

In 2000, the economic burden of depression was estimated at $83.1 billion in the US2 and researchers estimate that by the year 2020, depression will be the second leading cause of disability worldwide.3

Depression can be a lethal disease. In fact, each year in the US, over 30,000 people die by suicide, 60% of whom suffer from depression.4 Overall, women are almost twice as likely as men to suffer from depression; however, some experts feel that depression in men is under-reported.5 Depression has no racial, ethnic or socioeconomic boundaries. About two-thirds of those who experience an episode of depression will have at least one other episode in their lives6.

While the exact cause of depression is not known, the leading scientific theory is that depression is caused by an imbalance of the brain’s neurotransmitters. Neurotransmitters are chemical messengers that send signals between brain cells. Depression is most often treated with antidepressant medications. It is believed that antidepressant medications work by increasing the levels of these neurotransmitters. Learn about depression treatment options.

More than 4 million patients do not receive adequate benefit from antidepressants1 which may in part be due to intolerance to their side effects. For these patients, they need a new way back.

References:
  1. Kessler, RC, et al. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry, 2005 Jun: 62 (6):617-27.
  2. Greenberg, PE, et al. The economic burden of depressive disorders in the United States: How did it change between 1990 and 2000? Journal of Clinical Psychiatry. 2003; 64 (12): 1465-1475.
  3. Murray CJ, Lopez AD. Evidence-based health policy – lessons from the Global Burden of Disease Study. Science. 1996; 274 (5288): 740-743.
  4. Heron, Melonie, et al. Deaths: Final Data for 2006. National Vital Statistics Reports, 57 (14). April 17, 2009.
  5. Kessler, RC, et al. The epidemiology of major depressive disorder; results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23): 3095-3105.
  6. Data on file

Copyright © 2010 Neuronetics. All Rights Reserved Sitemap  | Privacy Policy  | Terms and Conditions  | Glossary

You are leaving www.NeuroStarTMS.com, a website of Neuronetics. Links to all outside websites are provided as a resource to our visitors. Neuronetics accepts no responsibility for the content of other websites.

Click here to continue.